Last reviewed · How we verify
Dendrid (IDOXURIDINE)
Dendrid (Idoxuridine) is a small molecule nucleoside analog antiviral drug originally developed by Allergan and currently owned by Alcon. It targets thymidine kinase, a key enzyme in viral replication, to treat herpes simplex keratitis. Approved by the FDA in 1963, Dendrid is off-patent and has no active Orange Book patents, making it available from generic manufacturers. However, there are currently no generic manufacturers listed. As an off-patent drug, its commercial status is subject to change.
At a glance
| Generic name | IDOXURIDINE |
|---|---|
| Sponsor | Novartis |
| Drug class | Nucleoside Analog Antiviral |
| Target | Thymidine kinase, cytosolic |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1963 |
Approved indications
- Herpes simplex keratitis
Common side effects
Key clinical trials
- Efficacy of an Intra-articular Injection of Botulinum Toxin A Associated With Splinting for Base-of-thumb Osteoarthritis (PHASE2,PHASE3)
- Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine (PHASE3)
- Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles (PHASE3)
- Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia (PHASE2)
- Botulinum Toxin Type A Block of the Otic Ganglion in Chronic Cluster Headache: Safety Issues (PHASE1,PHASE2)
- Feasibility Pilot for the ReBOO-trial (PHASE2)
- Reduction of Bladder Injection Pain With Belladonna Opiate Suppository (PHASE4)
- PET Scans in Patients With Locally Advanced Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |